Loading...
•
Jun 30, 2021
ADMA Biologics Q2 2021 Earnings Report
ADMA Biologics achieved record revenue growth and narrowed net losses in Q2 2021.
Key Takeaways
ADMA Biologics reported a record $17.8 million in total revenues for Q2 2021, a 129% increase over the same period in 2020. The company also narrowed its net loss compared to the previous year, driven by increased revenues and improved gross margins. ADMA anticipates exiting 2021 approaching an annualized revenue run rate of approximately $100 million or more.
Total revenues increased by 129% to $17.8 million compared to Q2 2020.
Net loss narrowed to $18.9 million, or $(0.15) per share, compared to a net loss of $20.2 million, or $(0.23) per share, in Q2 2020.
Company anticipates FDA approval of VanRx aseptic fill-finish machine in the second half of 2021.
ADMA is on track to operate 10 or more plasma collection centers by 2024.
ADMA Biologics
ADMA Biologics
Forward Guidance
ADMA anticipates exiting 2021 approaching an annualized revenue run rate of approximately $100 million or more and reiterates all previously communicated strategic and financial objectives.
Positive Outlook
- Anticipated benefits from the VanRx aseptic fill-finish machine, including cost efficiencies and contract manufacturing opportunities
- Expected benefits from the recent implementation of Haemonetics’ Persona® technology combined with our plasma collection network
- Goal of building and opening new plasma collection centers by 2024
- Meaningful gross margin improvement
- Operating efficiencies
Challenges Ahead
- Risks and uncertainties described in our filings
- Impact of COVID-19 on the Company’s financial results and business operations
- Company’s plasma collections and production
- Our ability to maintain plasma supply
- The outcome and timing of our BLA application for our new plasma centers and for FDA approval of our VanRx aseptic fill-finish machine